Biotech veteran and Stanford physician-scientist brings 30 years of translational research and regulatory experience to ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...

Copycats and false advertisements are also to blame for the increased threats. Stemming from social media testimonials all ...

A special live broadcast of award-winning star and CEO’s conversation will focus on advancements and regulations on ALS ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Embrelis marks a pivotal moment ...

A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and ...

A 2025 survey of over 150 drug developers reveals that multi-indication development strategies have become central to the evolving cardiometabolic drug pipeline. Among those surveyed, 83 percent ...

We started the company 17 years ago with the goal of helping cancer patients live longer and longer until they eventually outlive their disease. We can transform cancer into something that's more of a ...

The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (CT03767348) trial in advanced melanoma was not ...

The University of California, Berkeley’s incubator for life sciences Bakar Labs announced construction for a new research and ...

The EVERSANA AI Accelerator is our dedicated center of excellence designed to harness the power of artificial intelligence ...